Canaccord Genuity analyst Max Masucci maintained a Hold rating on Illumina (NASDAQ:ILMN) on Wednesday, setting a price target of $350, which is approximately 0.62% below the present share price of $352.19.
Masucci expects Illumina to post earnings per share (EPS) of $0.32 for the third quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Hold rating of shares in Illumina, with an average price target of $363.89.
The analysts price targets range from a high of $400 to a low of $310.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $633 million and a net profit of $96 million. The company's market cap is $51.42 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 38.7% and a 72.55% success rate.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.